Bordeaux, Boston, January 4, 2016: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announced today its schedule for the publication of financial information for 2016.
Event Dates*
2015 Full-Year Sales January 26, 2016
2015 Full-Year Results March 30, 2016
2016 First-Quarter Sales April 28, 2016
Annual General Meeting May 24, 2016
2016 First-Half Sales July 26, 2016
2016 First-Half Results September 26, 2016
2016 Third-Quarter Sales October 25, 2016
(*): Press releases are published after market closes. Subject to modification.
About IMPLANET
Founded in 2007, IMPLANET is a medical technology company that manufactures high-quality implants for orthopedic surgery. Its flagship product, the JAZZ latest-generation implant, aims to treat spinal pathologies requiring vertebral fusion surgery. Protected by four families of international patents, JAZZ has obtained 510(k) regulatory clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. IMPLANET employs 45 staff and recorded 2014 sales of €7.0 million. For further information, please visit www.implanet.com. Based near Bordeaux in France, IMPLANET established a US subsidiary in Boston in 2013. IMPLANET is listed on Compartment C of the EuronextTM regulated market in Paris.